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Abstract
The aim of this document is to provide specific recommendations on the use of cardiovascular magnetic resonance
(CMR) protocols in the era of the COVID-19 pandemic. In patients without COVID-19, standard CMR protocols
should be used based on clinical indication as usual. Protocols used in patients who have known / suspected active
COVID-19 or post COVID-19 should be performed based on the specific clinical question with an emphasis on
cardiac function and myocardial tissue characterization. Short and dedicated protocols are recommended.
Keywords: Recommendations, CMR, COVID-19, Protocol, Indication, SCMR, SARS-CoV-2, Cardiac MRI, Pandemic,
Heart
Purpose
Society for Cardiovascular Magnetic Resonance (SCMR)
guidance for the practice of cardiovascular magnetic res-
onance (CMR) during the COVID-19 pandemic have re-
cently been published [1]. The aim of this document is
to provide more specific recommendations on the CMR
protocols for scanning patients with known or suspected
severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-19) infection or those recovering from the disease.
These recommendations are not meant to be restrictive
but rather to serve as a general framework. They also
serve as the basis for registries and clinical studies in pa-
tients with SARS-CoV-2 infection, to ensure consistency
between local, national and international efforts. All rec-
ommendations will be updated continuously and pro-
vided online in the SCMR’s coronavirus disease 2019
(COVID-19) Preparedness Toolkit https://scmr.org/
page/COVID19.
Common CMR-indications in patients with
COVID-19
The effects of COVID-19 on cardiac structure, function,
and tissue properties are largely uncertain. First reports
are indicating potential myocardial injury or involvement
in the acute phase of COVID-19 and post infection [2–9].
CMR is the non-invasive imaging method of choice for
structural and functional evaluation of the heart and has
unique tissue characterization abilities and will therefore
play a key role in many patients recovering from COVID-
19 and cardiac involvement [10–12]. Adults and children
appear to have different presentations with some reports
of children being affected by a hyperinflammatory syn-
drome with acute myocarditis or Kawasaki-like clinical
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presentation [13, 14]. Based on recent literature, the fol-
lowing are the most likely indications for CMR in patients
with active or convalescent phase of COVID-19:
Expected CMR-indications in patients within active or
convalescent phase of COVID-19
Adults:
- Left- and right ventricular dysfunction (heart failure)
- Myocarditis (including systemic inflammatory disease, cardiotoxicity)
- Pericarditis
- Myocardial infarction with non-obstructive coronary arteries (MINOCA)
- Chest pain (chronic coronary syndrome)
- Acute myocardial infarction
- Stress induced cardiomyopathy (Takotsubo)




- Left- and/or right ventricular dysfunction (heart failure)




In many clinical scenarios, CMR protocols in the
context of COVID-19 infection will need to be short and
adapted to the breath-hold ability of patients. Short pro-
tocols also help to minimize exposure risks for health-
care personal and patients (Table). Whenever possible,
CMR studies should be postponed until patients are no
longer contagious so as to avoid exposure to scan
personnel. Recently, specific recommendations how to
perform CMR in the current COVID-19 pandemic have
been published by the SCMR [1] and European Associ-
ation of Cardiovascular Imaging (EACVI) [15]. Acquisi-
tion and reporting should follow general SCMR
guidance [16, 17]. If contrast administration is planned,
check of kidney function is recommended in COVID-19
patients, however not mandatory particularly with ap-
propriate (macrocyclic) contrast agents. Wherever pos-
sible, a COVID-19 dedicated CMR scanner should be
used for scanning patients with active infection.
Recommended CMR-protocols in adult patients with
active/post COVID-19




(SAx full coverage, LAX: 4Ch; 2Ch;
3Ch)
Minimum




(T1-native, T2, T1-post (calculate
ECV)
Desirable
Recommended CMR-protocols in adult patients with
active/post COVID-19 (Continued)
Acquisition based myocardial strain
(Tagging, DENSE, fSENC)
Optional





2D-flow (aorta & pulmonary arteries) Desirable
4D-flow Optional
Angiography (pulmonary vessels) Optional
Lung imaging Optional
2Ch = two chamber; 3Ch = three chamber; 4Ch = four
chamber; DENSE = displacement encoding with
stimulated echoes; ECV = extracellular volume fraction;
LGE = late gadolinium enhancement; SAx = short axis;
SENC = strain encoding; STIR = short tau inversion
recovery
Recommended CMR-protocols in children with active/post
COVID-19




(SAX full coverage, LAX: 4-CH; 2-CH; 3-CH)
Minimum




(T1-native, T2, T1-post (calculate ECV)
Desirable
Acquisition based myocardial strain
(Tagging, DENSE, fSENC)
Desirable
Late gadolinium enhancement (LGE) Minimum (SAX)
Desirable (long axis)
2D-flow (aorta & pulmonary arteries) Desirable
4D-flow Optional
Angiography (pulmonary vessels) Optional
3D sequence for coronary artery anatomy Desirable
Lung imaging
(T2 weighted Fat-suppressed sequences with
motion correction (free breathing with re-
spiratory triggered) for whole thorax in axial
plane)
Desirable
In patients with active COVID-19 or for those with
poor functional status, a short protocol (10–15 min) in-
cluding a minimum data set of cardiac function and
focal myocardial damage (late gadolinium enhancement
(LGE)- minimum single shot in short axis (SAx)-orienta-
tion) is recommended. In children with active/post
COVID-19 a 3D sequence for coronary artery imaging
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to detect eventual coronary dilation/ectasia in proximal
or mean segments of the coronary artery tree is recom-
mended. Data acquisition should be as short as possible
by using undersampling methods and or reductions in
spatial or temporal resolutions without loss of diagnostic
image quality. Use of free-breathing and real-time acquisi-
tion methods is encouraged. If the patient’s functional sta-
tus allows a scan time of around 30min, components
indicated as “Desirable” in the table should be added to
allow advanced tissue characterization and potential as-
sessment of myocardial ischemia. Patients with acute
COVID-19 infection often have respiratory compromise –
in which context risks of vasodilator (regadenoson/adeno-
sine) stress increased: Utility of pharmacolologic stress
should be considered on a patient specific basis, consider-
ing concomitant risks in the context of active COVID-19
infection. Optional components of the protocol can be
added according to the clinical question and patient con-
dition. Parametric mapping imaging acquisition and ana-
lysis should follow the SCMR recommendations [18].
Hematocrit should be noted at the time of the CMR exam.
Documentation of blood-pressure and heart rate at the
time of the CMR scan is recommended.
Scan interpretation and reporting
When interpreting CMR-exams, SCMR reporting guide-
lines should be followed [16, 17]. Based on literature pub-
lished to date, potential findings in COVID-19 patients
include acute and chronic myocarditis, pericarditis, left
and right heart failure, acute coronary syndromes, myo-
cardial infarction with normal coronary arteries,
Kawasaki-like coronary ectasia (expecially in children) and
Takotsubo cardiomyopathy. In addition, there may be a
high incidence of non-cardiac findings, specifically pul-
monary infiltrates or peripheral pulmonary vascular
anomalies, in patients with COVID-19. If additional (or
still persistent) pulmonary abnormalities are present at
CMR-exams, further evaluation should be recommended.
In order to improve understanding of the cardiovascular
effects of SARS-CoV-19 infection, SCMR is setting up a
global CMR registry with adult (CMR COVID-19) and
pediatric sections (CARDOVID study). Clnicians/scien-
tists/researchers involved in reporting CMR scans in
COVID-19 patients are encouraged to contribute to this
effort. More information at www.scmr.org. Individual
cases can be published in the SCMR COVID Case reposi-
tory at www.scmr.org.
Conclusion
According to the clinical indication, standard or rapid
protocols should be used for COVID-19 patients. Espe-
cially short and dedicated CMR examinations that focus
on the evaluation of cardiac morphology and function,
as well as myocardial tissue characterization are
recommended.
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